Thursday, September 18, 2025

Latest

Stifel Downgrades Aurora Cannabis Price Target To $3.60 Based On Liquidation Analysis

This morning, Stifel downgraded their 12-month price target on Aurora Cannabis (TSX: ACB) (NYSE: ACB) to C$3.60 from C$10.50 and reiterated its hold rating, based on a liquidation analysis of the company. This comes after a news release yesterday, where Aurora stated that they filed a shelf for US$500 million and gave an update to their balance sheet. Aurora currently has C$272 million in cash, $104 million in term debt, and the previous ATM is now fully utilized.

Andrew Carter, Stifel’s cannabis analyst, said that “This implies C$100 million of cash burn outside scheduled payments over the past 118 days suggesting significant downside to our previous estimates.” Carter then states that the ATM usage after the earnings release means that there was an additional 31% of dilution that happened to Aurora shareholders, with an average share price 34% below the 9/21/2020 close, “calling into question the company’s comfort with the pace at which the business can recover.”

Carter has lowered their fiscal first-quarter and full-year 2021 and 2022 estimates down by quite a bit. Stifel now guides revenue to be C$54 million and EBITDA to be (C$13) million for the first fiscal quarter, compared to their previous estimate of C$62 million and (C$5) million, respectively. Fiscal 2021 and 2022 revenue is now forecasted to be C$272 and $381 million, respectively. These numbers are down from $325.9 and $457.5 million.

Carter adds that between the overwhelmingly negative sentiment after Aurora’s earnings and the massive ATM issuances, “suggests in our view the business is performing well below company expectations.” He then adds, “Conversely, if the company is on track, utilizing the ATM at this magnitude with the average share price 34% below the 9/21/2020 close would suggest a complete mismanagement of the capital markets.”

Andrew Carter then circles back to previous rumors that Aurora was in merger negotiations with Aphria. At the time, Aurora had no CEO, and Stifel put out a note giving a worst-case estimate of C$8.88, which has now been cut to C$4, assuming there are still some negotiations going on. Although Carter had this to say, “we believe Aurora significantly overestimated its case for independent value creation simply engaging in meaningful discussions that reached this level let alone rejecting an offer to participate in the growth of a much stronger combined vehicle”.

Finally, Carter closes the note off by stating, “Absent sustained improvement in fundamentals which we believe will be difficult, we believe Aurora will be challenged to drive investor interest let alone sustained enthusiasm.”


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why $10K Gold No Longer Sounds Crazy | Dan Wilton – First Mining Gold

The Pure Silver Set Up! | Joaquin Marias – Argenta Silver Corp

Why $30,000 Gold Isn’t Crazy! | Simon Marcotte – Northern Superior

Recommended

Canadian Copper Secures $8 Million Lead Order From Ocean Partners As Part Of Larger Funding Round

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Related News

Snowflake: Canaccord Expects Long Term Guidance Of $10 Billion In Revenues To Remain Intact

Snowflake (NYSE: SNOW) last week reported its third-quarter financial results. The company announced that product...

Sunday, December 4, 2022, 01:24:00 PM

Aurora Cannabis To Conduct 10 To 1 Reverse Split To Meeting Nasdaq Listing Requirements

In an effort to remain listed on the Nasdaq, Aurora Cannabis (TSX: ACB) has seen...

Wednesday, January 31, 2024, 08:22:26 AM

Aphria: Canaccord Downgrades Company To Hold From Speculative Buy

Earlier this week, it was announced that Aphria Inc (TSX: APHA) (NASDAQ: APHA) and Tilray...

Friday, December 18, 2020, 12:05:00 PM

Meta Platforms: Canaccord Anticipates Headwinds To Persist, Cuts Target To $200

On October 26th, Meta Platforms Inc (Nasdaq: META) reported its third-quarter financial results. The company...

Thursday, November 3, 2022, 12:52:00 PM

Canadian Cannabis: Canaccord Lifts Cronos Target, Reiterates Canopy Growth And Tilray Ratings

Yesterday Canaccord Genuity Capital Markets put out a second-quarter preview note on the top Canadian...

Thursday, July 28, 2022, 03:02:00 PM